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Abstract Over recent years routine ultrasound scanning has
identified increasing numbers of neonates as having
hydronephrosis and pelvi-ureteric junction obstruction
(PUJO). This patient group presents a diagnostic and manage-
ment challenge for paediatric nephrologists and urologists. In
this review we consider the known molecular mechanisms
underpinning PUJO and review the potential of utilising this
information to develop novel therapeutics and diagnostic bio-
markers to improve the care of children with this disorder.
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Introduction
Antenatally detected hydronephrosis is a major clinical dilem-
ma for paediatric nephrologists and urologists (incidence of 1
in 200) [1]. This condition has become more prevalent in
recent years as antenatal scanning has become more sensitive
and widely used. Approximately one in seven neonates with
antenatally detected hydronephrosis has pelvi-ureteric junc-
tion obstruction (PUJO) [2–4], making PUJO one of the most
common causes of congenital urinary tract obstruction, with
an incidence of one in 1000 to one in 2000 live births [3–5].
Interestingly, males are affected approximately threefold more
frequently than females by this condition [4]. The reason for
this difference is unknown.
Intrinsic obstruction due to an adynamic stenotic segment
at the PUJ is the most common aetiology (75% of cases) [4],
with failure of peristalsis producing an incomplete, functional
obstruction. Other causes include: crossing vessels (20%),
peripelvic fibrosis, abnormal ureteric insertion, fibroepithelial
polyps and anatomical variants, such as retrocaval ureter,
horseshoe and duplex kidneys [4, 6, 7].
The major challenge for clinicians is deciding which of
these children, who are largely asymptomatic, require a
pyeloplasty to relieve the obstruction. This is because two-
thirds of children with PUJO do not sustain renal damage or
need surgery, and their hydronephrosis spontaneously im-
proves [8–10].
Currently, serial ultrasound and invasive isotope studies are
performed to guide surgical management of PUJO [4].
However, the ability of these diagnostic modalities to accu-
rately detect obstruction, identify children at risk of functional
deterioration and predict the need for surgery is questionable.
Additionally, there remains debate regarding the parameters
which indicate clinically significant obstruction [9, 11–13].
In general a pyeloplasty is performed for [6]:
& differential renal function deterioration (differential func-
tion of <40% or a fall of >10% on serial MAG3
renograms)
& significant hydronephrosis with a renal pelvis
anteroposterior diameter of >3 cm on ultrasound scan
& increasing hydronephrosis with an increasing
anteroposterior diameter on serial ultrasound scan
& symptomatic children.
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Our current understanding of the natural history of PUJO
as well as our ability to distinguish which children require
surgery is inadequate. Available diagnostic tests cannot accu-
rately discern between children with PUJO that will resolve
spontaneously and those with PUJO that will persist, causing
functional impairment. Consequently, despite radiological
monitoring, there is a risk of loss of function in the affected
kidney while the patient is under observation [14].
In this review we discuss the currently known molecular
mechanisms underlying intrinsic PUJO and whether this in-
formation could contribute to the future development of novel
therapies and diagnostic biomarkers.
Anatomy of the upper urinary tract
The PUJ is a region of gradual transition from the funnel-
shaped renal pelvis to the proximal ureter [15] (Fig. 1). It is a
physiologic sphincter [16] that is characterised by prominent
luminal folds with increased muscle thickness capable of cre-
ating a high-pressure zone to regulate urine flow. Similar to the
adjacent renal pelvis and ureter, the PUJ comprises three main
layers: the inner urothelium, middle smooth muscle and outer
adventitia [15]. Smooth muscle contraction propels urine from
the renal pelvis to the bladder [17], coordinated by submucosal
and intra-muscular nerve plexi [18] and modulated by auto-
nomic innervation involving a range of neurotransmitters that
include acetylcholine, noradrenaline, substance P, neurokinin
A, calcitonin gene-related peptide, neuropeptide Y, vasoactive
intestinal peptide and nitric oxide (NO) [17].
Embryology of the ureter and PUJ
Understanding the normal embryology of PUJ formation is
vital when considering where development may proceed in-
correctly in congenital abnormalities such as PUJO. The kid-
ney develops from metanephric mesoderm as far along the
nephron as the distal tubules. The collecting duct onwards,
including the major and minor calyces, renal pelvis and ure-
ter has a different embryological origin, arising from the
ureteric bud [19, 20]. Thus, the PUJ does not represent an
embryological fusion site, rather it is derived exclusively
from the ureteric bud. The important molecular pathways
that form the ureter and PUJ are shown in Fig. 2 and
Table 1 [15, 26–28]. Briefly, the ureteric bud, consisting of
a simple epithelial layer extending into loose mesenchyme,
arises from the mesonephric duct during the fifth week of
gestation in humans [26]. Epithelial cell proliferation and
differentiation then results in the formation of the transitional
epithelium. Epithelial paracrine and mesenchymal autocrine
signalling stimulates the formation of smooth muscle cells
from mesenchyme, which begins at 12 weeks of gestation in
humans [26, 29]. Mouse models have implicated a num-
ber of signalling molecules in this process of prolifera-
tion, aggregation, differentiation and orientation of
smooth muscle cells as they encircle the urothelial tube
(Fig. 2, Table 1). A second phase of smooth muscle
differentiation that particularly affects the renal pelvis
and proximal ureter occurs in postnatal mice (equivalent
to the second trimester of gestation in humans) and is
regulated by calcineurin and angiotensin II signalling
[30, 31].
Fig. 1 Diagrammatic
representation of the pelvi-
ureteric junction (PUJ). The
gradual transition from the renal
pelvis to the proximal ureter is
illustrated as well as the increased
mucosal folds and smooth muscle
thickening in this region
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Pathologic features of intrinsic PUJO
Inflammatory cell infiltration [32], varying degrees of
fibrosis, excess collagen deposition [32–35] and abnor-
mal muscle fibre arrangement [36] are present in human
intrinsic PUJ obstruction. Both muscular hypertrophy/
hyperplasia [32, 34, 37] and atrophy/hypoplasia [32,
36] are reported alongside depletion of nerves to the
muscular layer [33]. These findings are noted when
the PUJ is excised at pyeloplasty and therefore represent
late features of PUJ obstruction (Fig. 3). Although the
time course of PUJ disease progression is unknown in
humans, genetic mouse models of hydronephrosis show
abnormalities of peri-urothelial mesenchymal organisa-
tion as early as embryonic day (E) 12.5 (approximately
equivalent to 35 days of gestation in humans) [24] and
smooth muscle cell differentiation at E15.5 (approxi-
mately equivalent to 12 weeks of gestation in humans)
[23]. One week postnatally (approximately equivalent to
humans at birth) mice with Id2 haploinsufficiency show
smooth muscle irregularity and hypertrophy at the PUJ
[38], features which are common to human PUJO. The
possible mechanisms underlying this pathology are de-
scribed later in this review.
Modelling PUJO to understand its molecular biology
Adult and neonatal rodent models of complete and partial
unilateral ureteric obstruction (UUO) have been extensive-
ly used to investigate the molecular biology of congenital
obstructive nephropathy. Neonatal models are particularly
helpful because rodent nephrogenesis continues for 1 week
postnatally and nephron maturation over the subsequent
week. Thus, at birth and 1 week of age, rodent kidney
development is equivalent to humans at the second
Fig. 2 Embryological signalling pathways of the PUJ. The ureteric bud
arises from the mesonephric duct and initially consists of only a simple
epithelial layer extending into loose mesenchyme. Epithelial cell
proliferation and differentiation to form transitional epithelium leads to
luminal obliteration, which at the end of the embryonic period is corrected
by physiologic recanalisation of the ureter. Epithelial paracrine and
mesenchymal autocrine signalling stimulates the proliferation and
differentiation of the mesenchyme into smooth muscle cells (SMC)
which aggregate and orientate so as to encircle the epithelial tube.
Specifically, the urothelium secretes SHH which activates the PTCH1
receptor on adjacent mesenchyme, thereby stimulating mesenchymal
proliferation. Mesenchymal cells (MC) express TBX18, a T-box
transcription factor, which enables the correct localisation and aggrega-
tion of the former around the urothelium. The mesenchymal cells also
express BMP4 which acts in an autocrine manner to upregulate TSHZ3
andMYODC.MYODC enables differentiation of SMC by increasing the
transcription of genes encoding smooth muscle contractile proteins.
DLGH1, expressed by the urothelium and SMC, is responsible for the
correct orientation of SMC around the urothelial tube. In postnatal mice
(equivalent to second trimester of gestation in humans), increased
urine production matches the development of the renal pelvis and
is accompanied by a second phase of muscle differentiation that
particularly affects the renal pelvis and proximal ureter, regulated
by calcineurin and angiotensin II signalling. The timeline refers to
days of gestation (E embryonic day) in mouse models. MD
Mesonephric duct, UB ureteric bud, MC mesenchymal cells. See
Table 1 for description of factors active in the pathways involved
in ureteric development
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trimester of gestation and birth, respectively [11]. This
gives a window in which surgery can be performed on
the animals to mimic in utero obstruction in humans.
Adult obstructive models show a broadly similar patholog-
ic progression to neonatal models with the exception that
neonatal obstruction impedes normal maturation and
growth of the kidney and leads to early nephron loss.
The renal pathologic findings in neonatal and adult UUO
models and the timescale of their development are present-
ed in Fig. 4 [39–47].
A comprehensive review comparing neonatal models with
human disease confirms their validity for investigating ob-
structive nephropathy and will not be further discussed in this
review [48].
Proposed molecular mechanisms underpinning
PUJO
In the following subsections we highlight some of the molec-
ular steps that may lead to the development of intrinsic PUJO
and subsequent obstructive nephropathy. Data have been ob-
tained from both adult and neonatal models of complete and
partial ureteric obstruction alongside evaluation of tissue ob-
tained at pyeloplasty for human PUJ obstruction.
Neurogenic factors
Light microscopy studies have revealed reduced innervation
within the muscular layer of the PUJ in human specimens
Fig. 3 Pathologic features of
intrinsic PUJO. Reduced luminal
mucosal folds, excess collagen
deposition, depletion of nerves
within the muscular layer,
abnormal muscle fibre
arrangement, inflammatory
infiltrate and both muscle
hypertrophy/hyperplasia and
muscle atrophy/hypoplasia are
seen at the PUJ in human PUJO
Table 1 Proteins/molecular
pathways involved in ureteric
development
Protein Full protein name Function Reference
SHH Sonic hedgehog Morphogen which stimulates
peri-urothelial mesenchymal cell pro-
liferation and regulates timing of
smooth muscle cell differentiation
[21]
PTCH1 receptor Protein patched homolog 1 Receptor for SHH, functions as tumour
suppressor when unbound
[21]
BMP4 Bone morphogenetic protein 4 Growth factor, necessary for smooth
muscle cell differentiation and ureter
morphogenesis
[22]
TSHZ3 Teashirt zinc finger homeobox 3 Transcription factor-like protein neces-
sary for myocardin expression and
ureteric smooth muscle cell differenti-
ation
[23]
MYOCD Myocardin Transcriptional co-activator, necessary
for expression of contractile proteins
[23]
TBX18 T Box protein 18 Transcription factor necessary for correct
localisation and aggregation of smooth
muscle cells around ureteric
urothelium
[24]
DLGH1 Disks large homolog 1 Scaffolding protein, regulates smooth
muscle cell orientation
[25]
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excised at pyeloplasty for PUJO [33]. This is associated with
reduced expression of molecular markers, including glial cell
line-derived neurotrophic factor (survival factor for neurons),
protein gene product 9.5 (general neuronal marker), and nerve
growth factor receptor protein, in the muscle layers of the
stenotic PUJ compared to controls. Although it is speculated
that these neuronal changes may contribute to the
pathogenesis of PUJO, there is as yet no evidence to confirm
or refute this notion. Conflicting changes in synaptophysin
(e.g. major synaptic vesicle protein p38) expression in terms
of both amount (increased and decreased) and distribution
(localisation to the nucleus) are reported in PUJO compared
to controls and are of uncertain significance. S-100 (schwann
cell marker) and neurofilament (neuronal protein) expression
Fig. 4 Pathologic features of
rodent models of unilateral
ureteric obstruction (UUO).
Timeline of the development of
renal pathogenic features in
neonatal and adult models of
UUO. CUUO Complete UUO,
PUUO partial UUO
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are unchanged, demonstrating there is not a global reduction
in neuronal components [34, 49].
Myogenic factors
Together with increased smooth muscle cell apoptosis, pheno-
typic and cytoskeletal smooth muscle cell changes are seen in
the human PUJ excised at pyeloplasty for PUJO. The stenotic
PUJ shows significantly increased expression of smooth mus-
cle myosin heavy chain isoforms 1 and 2 [37], as well as an
altered ratio of integrin (transmembrane signalling receptor)
isoform expression compared to control samples [50]. The
preferential expression of immature integrins in the stenotic
PUJ [50] may indicate developmental delay of the smooth
muscle cells, potentially contributing to their altered function
and increased apoptosis in PUJO.
Supporting a myogenic cause of PUJO, transgenic mouse
models targeting smooth muscle differentiation generate a
PUJ phenotype with hydronephrosis secondary to functional
obstruction (Table 2).
Table 2 Evidence from animal and human studies of genes potentially involved in the pathogenesis of pelvi-ureteric junction obstruction
Gene Full gene name Animal Features and mechanism Human Reference
Ace Angiotensin converting
enzyme
Ace−/− mice Hydronephrosis, renal
parenchymal atrophy
[51]
Adamts-1 A disintegrin-like and
metallopeptidase with
thrombospondin type 1
motif, 1
Adamts-1−/−
mice
PUJ obstruction, increased
collagen at PUJ. Other
urogenital anomalies.
[52]
Agt Angiotensin Agt−/− mice Hydronephrosis, renal
parenchymal atrophy,
[53]
Agtr 1a/b Angiotensin II receptor type 1
(1a and 1b)
Agtr1−/− (1a and
1b) mice
Hydronephrosis in older mice,
renal parenchymal atrophy,
failure of renal pelvis
development, ureteric
smooth muscle hypoplasia
and abnormal peristalsis
[31]
Aqp2 Aquaporin 2 Aqp2S256L/S256L
CPH mice
Mutation in CPH mice
prevents Aqp2
phosphorylation and
normal trafficking.
Hydronephrosis secondary
to polyuria
[54]
Calcineurin Calcineurin. Also known as
Protein phosphatase 3
(ppp3)
Pax3-CreT/+;
Cnb1flox/ flox
mice
Calcineurin inactivation in
metanephric and ureteral
mesenchyme giving
hydronephrosis, abnormal
pyeloureteral peristalsis
with defective renal pelvis
and smooth muscle
development
[30]
Id2 Inhibitor of DNA binding 2 Id2−/− and Id2
+/− mice
Hydronephrosis and PUJ
development
[38]
Nfia Nuclear factor I/A Nfia+/− and
Nfia−/− mice
Hydroureteronephrosis, VUR,
abnormal PUJ and VUJ
development. CNS
malformations.
Nfia +/−due to chromosomal
translocation and deletion.
VUR and CNS
malformations.
[55]
TBX18 T-box transcription factor Tbx18−/− mice Hydroureteronephrosis, short
ureters, ureteric smooth
muscle defects due to
abnormal smooth muscle
cell differentiation and
localisation
Hispanic family with
autosomal dominant
CAKUT predominantly
PUJO. Heterozygous
truncating mutation
(c.1010delG) of Tbx18
[24, 56]
Tshz2 and 3 Teashirt zinc finger family
member 2 and 3
Tshz3−/− mice Hydronephrosis with PUJ
configuration, abnormal
smooth muscle
differentiation proximal
ureter
Tshz2/Tshz3 mutations not
cause of PUJO in
Albanian/Macedonian
population
[57, 58]
CAKUT, Congenital anomalies of the kidney and urinary tract; CNS, central nervous system; CPH, congenital progressive hydronephrosis; PUJO, pelvi-
ureteric junction obstruction; VUJ, vesico-ureteric junction; VUR, vesico-ureteric reflux
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Increased pressure, impeded blood supply and hypoxia
Obstructive hydronephrosis is associated with a doubling to
trebling of renal pelvis pressure [16, 59–61]. The resultant
increased intratubular hydrostatic pressure [62] stimulates
the renopathogenic effects of obstruction via three proposed
mechanisms, namely, (1) tubular ischaemia due to hypoperfu-
sion, (2) pressure-induced mechanical stretch/compression of
tubular cells and (3) altered urinary shear stress. The latter two
mechanisms are likely to be the primary inducers of obstruc-
tive renal injury [48], causing dysregulation of many cyto-
kines, growth factors, enzymes and cytoskeletal proteins
(Table 3), resulting in early renal haemodynamic changes
followed by structural and functional alterations to the entire
nephron. Figure 5 highlights the major mechanisms of renal
injury in PUJO.
Following a short initial increase in renal blood flow
related to local vasodilator production [48], the intra-
renal renin–angiotensin–aldosterone system (RAAS) is
activated causing pre- and post-glomerular vasoconstric-
tion and a resultant fall in renal blood flow (RBF),
medullary oxygen tension and glomerular filtration rate
(GFR) [11, 48, 64, 80, 88–90]. Proximal tubular hypox-
ia and necrosis in neonatal rats with UUO suggest that
vasoconstriction causes segment-specific ischaemic injury
[91]. Accordingly, angiotensin II receptor, type 1 (AT1 recep-
tor) inhibition improves tubular function by increasing RBF
and GFR [92].
Reduced urine production and continuing urine drain-
age by venous and lymphatic systems together with
tubular and renal pelvis dilatation result in a subsequent
decline in renal pelvic pressure [48, 89, 93], which may
be a compensatory mechanism to limit damaging in-
creased intra-renal pressure [93].
Initiation of proinflammatory cytokines
Cytokines in the stenotic PUJ
Transforming growth factor-beta (TGF-β) expression is noted
in human stenotic PUJ compared to normal controls [94].
Furthermore, the smooth muscle regulators endothelin-1
(smooth muscle constrictor) and adrenomedullin (smooth
muscle relaxant) have been shown to be increased and
decreased, respectively, in stenotic PUJ disease [95].
Analysis of paediatric renal pelvis tissue proximal to the
PUJO for cytokines that show altered renal expression in
nephropathy demonstrates increased TGF-β and reduced
macrophage inflammatory protein-1alpha (MIP-1α). In
contrast, epidermal growth factor (EGF), monocyte che-
motactic peptide 1, interferon-γ-inducible protein 10 and
RANTES (regulated on activation normal T-cell
expressed and secreted) mRNA expression are unchanged,
suggesting that TGF-β and MIP-1α play important roles in
the development of PUJO [88, 96].
Intra-renal cytokines
Increased intra-renal angiotensin II activates nuclear factor
kappa B and ROCK (rho-associated coiled-coil-forming
protein kinase), leading to cytokine release and interstitial
macrophage infiltration and activation. Intra-renal selectins,
integrins, intercellular-adhesion molecule 1, vascular cell
adhesion molecule 1, interleukin 1, monocyte chemoattractant
peptide 1, colony stimulating factor 1 and osteopontin
expression are all involved in macrophage stimulation
[11, 48, 88, 97]. Therefore, it appears that renal signals
initiate and maintain the injurious inflammatory response to
PUJO. Accordingly, both selectin and β2-integrin knockout
mouse models show reduced macrophage infiltration into the
obstructed kidney after UUO [43, 44].
Inflammatory infiltrates
Activated macrophages infiltrate the renal interstitium, sus-
taining the inflammatory response by releasing cytokines,
such as TGF-β1, tumour necrosis factor-alpha (TNF-α), and
platelet-derived growth factor [11, 88].
Profibrotic processes
Tubulointerstitial fibrosis is the final common pathway for
many chronic kidney disorders, including obstructive
uropathy, and is instigated by altered cytokine expression
(Table 4). Activated resident interstitial myofibroblasts [98],
expressing α-smooth muscle actin (boosts cell contractility)
[99], aggregate, proliferate and produce extracellular matrix.
Extracellular matrix consisting of collagens I, III and IV,
fibronectin, laminin and proteoglycans accumulates due to
increased synthesis and reduced degradation [74, 100, 101].
Myofibroblasts amplify fibrosis by producing cytokines, in-
cluding TGF-β1 and TNF-α [11]. Parenchymal damage and
renal dysfunction results, such that in children with PUJO the
extent of fibrosis significantly correlates with differential renal
function [102].
Angiotensin II upregulation is central to the pathogenesis
of obstructive nephropathy (Fig. 6) [11, 41, 45, 64, 68, 83, 84,
91, 103–112]. Angiotensinogenmurine knockout studies have
demonstrated that angiotensin II expression is responsible for
at least 50% of renal fibrosis in chronic neonatal UUO [104].
Acting predominantly via the AT1 receptor [45, 105, 113] it
regulates cytokine production and stimulates reactive oxygen
species (ROS) generation, which in turn propagates the
proinflammatory, fibrogenic state [48, 104]. The generation
of ROS also causes proximal tubular degeneration by apopto-
sis, autophagy and necrosis, with consequent destruction of
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Table 3 Table showing the major cytokines, growth factors, chemokines, enzymes and cytoskeletal proteins which demonstrate altered intra-renal
regulation in obstructive nephropathy, the timing of these changes and their mode of action
Proteina Action Change/timing Species Reference
Angiotensin II Vasoregulatory,
proinflammatory,
proapoptotic, profibrotic
Increased 28 days
Increased 1 week and 5 weeks
Increased after mechanical stretch
Neonatal rat CUUO
Adult rat CUUO
In vitro podocytes
[63]
[64]
[65]
α-SMA Increases myofibroblast
contractility/EMT marker
Increased 5 days
Increased 4 days
Neonatal rat CUUO
Adult mouse CUUO
[39]
[66]
Caspases Proapoptotic Increased 14 days
Increased 1 day
Neonatal rat CUUO
Adult rat CUUO
[67]
[68]
Clusterin Cytoprotective via
pro-survival autophagy
Increased 5 days Neonatal rat CUUO [39]
COX-2 Polyuria and natriuresis,
anti-apoptotic, antifibrotic
Increased 24 h
Increased 3 days (mRNA)
Adult rat CBUO
Adult mouse CUUO
[69]
[70]
CTGF Profibrotic Increased 2 days (mRNA) Adult rat CUUO [45]
EGF Epithelial survival factor Decreased 7 days (mRNA) (Undetectable
expression in neonatal rat kidney before
4 days)
Decreased 33 days
Decreased at pyeloplasty (mean age 2 years)
(mRNA)
Decreased at pyeloplasty (mean age 5 years)
Neonatal rat CUUO
Neonatal rat both CUUO and
5 day CUUO then release
Human renal biopsy
Human renal biopsy
[71]
[39]
[72]
[73]
ET-1 Vasoconstrictor Increased 2 days (mRNA) Adult rat CUUO [45]
Fas-L Proapoptotic Increased 1 day (mRNA) Adult rat CUUO [68]
HSP-70 Antiapoptotic Decreased 14 days Neonatal CUUO [67]
ICAM-1 Proinflammatory Increased 3 days Adult mouse CUUO [74]
Il-6 Proinflammatory Increased 2 days (mRNA) Adult rat CUUO [45]
Integrin (β1) Profibrotic Increased 3 days
Increased after mechanical stretch
Adult mouse CUUO
In vitro proximal tubular cells
[75]
[76]
MCP-1 Proinflammatory Increased 12 days, no change 4 days
Increased 2 days (mRNA)
Increased at pyeloplasty (mean age 2 years)
(mRNA)
Neonatal rat CUUO
Adult rat CUUO
Human renal biopsy
[77]
[45]
[72]
MMP 2 and 9 ECM degradation Decreased 3 days Adult mouse CUUO [74]
PAI-1 Profibrotic, inhibits ECM
degradation
Increased 7 days Adult mouse CUUO [78]
PDGF Profibrotic Increased 4 days Adult mouse CUUO [66]
NF-κB Regulatory transcription factor Increased 2 days Adult mouse CUUO [45]
Nitric oxide Vasodilator, anti-apoptotic,
antifibrotic
Decreased 14 days Neonatal rat CUUO [67, 79]
Renin Cleaves angiotensinogen,
upregulates
renin–angiotensin system
Increased 3 days (mRNA)
Increased 5 days
Increased 14 days (mRNA)
Increased 4–5 weeks
Increased 24 h
Increased after mechanical stretch
Neonatal rat CUUO
Neonatal rat CUUO
Neonatal rat CUUO
Neonatal rat CUUO
Adult rat CUUO
In vitro proximal tubular cells
[71]
[39]
[63]
[80]
[81]
[82]
TGF-β Proinflammatory,
proapoptotic, profibrotic,
stimulates EMT
Increased 1 day (mRNA)
Increased 33 days
Increased 3 days (mRNA)
Increased at pyeloplasty (mean age 5 years)
Neonatal rat CUUO
Neonatal rat both CUUO and
5 day CUUO then release
Adult rat CUUO
Human renal biopsy
[71]
[39]
[83]
[73]
TIMP-1 Profibrotic, inhibits ECM
degradation
Increased 5 days
Increased 3 days
Adult rat CUUO
Adult mouse CUUO
[84]
[74]
TNF-α Proapoptotic,
proinflammatory
Increased 14 days (mRNA)
Increased 1 day
Increased 2 days (mRNA)
Increased 1 day
Neonatal rat CUUO
Adult rat CUUO
Adult rat CUUO
Adult rat CUUO
[85]
[68]
[45]
[68]
VCAM-1 Proinflammatory Increased 3 days (mRNA) Adult mouse CUUO [86]
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the glomerulotubular junction, resulting in the formation of
atubular glomeruli [41, 109].
TGF-β1 is a profibrotic cytokine and fibroblast chemo-
attractant which plays a major role in fibrosis development
via SMAD-dependent and -independent pathways (Fig. 7)
[74–76, 114–118]. Renal TGF-β expression is increased in
experimental UUO [83, 103, 105, 107, 119–121] and children
with PUJO, being positively correlated with the histopatho-
logic grade, radioisotope drainage half time (t1/2) and post-
void washout and negatively correlated with pre-operative
differential renal function [73, 122].
Nitric oxide is an endogenous vasodilator that protects
against tubulointerstitial fibrosis and proximal tubular oxidant
injury in obstructive nephropathy [79, 84, 123]. Animal
models [111, 124, 125] and human studies of PUJO show
altered endothelial NO synthase (eNOS) and inducible NO
synthase (iNOS) expression/activity together with reduced
NO production. Lower eNOS expression/activity is associated
with worse creatinine clearance, reduced differential renal
function [90, 126] and increased fibrosis [90, 126], oxidant
injury and apoptosis [67, 79].
Antifibrotic processes
Renal cyclooxygenase 2 (COX-2) expression and prostaglan-
din production in experimental UUO is increased [69] and
may be a protective response. COX-2 inhibition worsens
obstructive nephropathy, while prostacyclin analogue
Fig. 5 Major mechanisms of renal injury in PUJO. GFR glomerular
filtration rate, TGF transforming growth factor
Table 4 Cytokines,
growth factors, enzymes
and adhesion molecules
promoting or preventing
tubulointerstitial fibrosis
in ureteric obstruction
Molecules
PROMOTING
tubulointerstitial
fibrosis in ureteric
obstruction
Molecules
PREVENTING
tubulointerstitial
fibrosis in ureteric
obstruction
Angiotensin II EGF
CTGF MMP
ICAM-1 Nitric oxide
Integrins VEGF
PAI-1
PDGF
TGF-β
TIMP-1
PAI-1, Plasminogen activator inhibitor 1;
PDGF, platelet-derived growth factor
Table 3 (continued)
Proteina Action Change/timing Species Reference
VEGF (podocytes) Endothelial survival factor Increased 28 days
Decreased 14 days
Neonatal PUUO
Neonatal CUUO
[87]
[87]
VEGF (tubules) Endothelial survival factor Variable expression
Decreased 14 days
Neonatal PUUO
Neonatal CUUO
[87]
[87]
Vimentin Intermediate filament protein/
EMT marker
Increased 5 days Neonatal rat CUUO [39]
WT-1 Transcriptional regulator, key
role in renal development
Decreased 14 days Neonatal rat CUUO [85]
Change is compared to sham animal or control human kidney and refers to protein expression unless otherwise stated. Timing is days after creation of
unilateral ureteric obstruction (UUO)
CUUO, Complete UUO; CBUO complete bilateral ureteric obstruction; PUUO, partial UUO
aα-SMA, Alpha-smooth muscle actin; COX-2, cyclooxygenase 2; CTGF, connective tissue growth factor; ECM, extracellular matrix; EGF, epidermal
growth factor; EMT, epithelial–mesenchymal transition; FasL, Fas ligand; HSP-70, heat shock protein 70; ICAM-1, intercellular adhesion molecule 1;
IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein 1; MMP, matrix metalloproteinase; NF-κB, nuclear factor kappa-light-chain-enhancer of
activated B cells; TGF-β, transforming growth factor-beta; TIMP-1, tissue inhibitor of metalloproteinases 1; TNF-α , tumour necrosis factor-alpha;
VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor; WT-1, Wilms tumor protein
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(ONO-1301) supplementation alleviates UUO-induced
fibrosis [127].
Cellular apoptosis
Apoptosis affects podocytes and endothelial and epithelial
cells within the kidney, leading to loss of glomeruli,
peritubular capillaries and tubules [11]. Tubular cell mechan-
ical stretch is a potent stimulator of apoptosis [91, 128] that is
mediated via TGF-β1 and TNF-α [68, 110] released from
tubular cells and infiltrating macrophages [88]. Other
proapoptotic factors increased after UUO include Fas-L [45],
p53, caspases and ceramide [11].
Downregulation of anti-apoptotic factors, including EGF,
eNOS, NO, vascular endothelial growth factor, heat shock
protein 70 and Wilms tumour-1, compounds the renal injury
[11, 67, 88, 128, 129].
Tubular function impairment
Ureteric obstruction leads to reduced renal expression of the
V2 (vasopressin) receptor [130], renal sodium and urea trans-
porters [131–133] and aquaporins [134–136]. Aquaporins are
a family of transmembrane proteins normally expressed by
mammalian kidney [137] and urothelium [138, 139] that
mediate water movement across the cell membrane along an
osmotic gradient [140]. Reduced renal aquaporin expression
Fig. 6 Major pathways involved
in the development of obstructive
nephropathy derived from animal
and human studies. ET-1
Endothelin 1, iNOS inducible
nitric oxide synthase, PT
proximal tubule, RAAS renin–
angiotensin–aldosterone system,
RANTES regulated on activation
normal T-cell expressed and
secreted, RBF renal blood flow,
ROS reactive oxygen species. For
other abbreviations, see footnotes
to Tables 3 and 4
Pediatr Nephrol
in experimental UUO is noted within 24 h of complete ob-
struction [134]. Similarly, renal aquaporins are downregulated
in children undergoing pyeloplasty, and in both human
and animal models this reduction is associated with
polyuria and reduced concentrating ability following
relief of obstruction [141–143].
Genetic mechanistic clues in PUJO
Phenotypes similar to PUJO have been noted in numerous
transgenic mouse models. Many genes involved in ureteric
smooth muscle proliferation and differentiation are implicat-
ed, supporting a primary myogenic aetiology. Importantly,
one of these genes has been implicated in human disease
(Table 2).
Mutations in TBX18, the gene coding for T Box pro-
tein 18, have been reported in association with congen-
ital anomalies of the kidney and urinary tract (CAKUT).
In particular, a heterozygous TBX18 truncating mutation
(c.1010delG) showing autosomal dominant inheritance
has been described across four generations of a family
with CAKUT, and predominantly PUJO [56]. The tran-
scription factor TBX18 is necessary for normal smooth
muscle cell proliferation, differentiation and localisation
around the developing urothelial stalk [24]. TBX18 also
directs epithelial proliferation and when absent leads to
an abnormally short ureteric bud [28].
In the majority of patients, however, PUJO is a poly-
genic disorder without an obviously inherited genetic
component [11].
Potential therapeutic molecular targets in PUJO
Human and animal studies have highlighted a number of
potential therapeutic targets that could be manipulated to alle-
viate the nephropathy sustained secondary to PUJO. Several
drugs targeting these pathways have been assessed in rodent
UUO models as described below, however, to our knowledge
none of these therapies have been trialed in childhood human
PUJO.
Angiotensin-converting enzyme and AT1 receptor
inhibitors
In adult rodent UUO models angiotensin-converting enzyme
(ACE) inhibitors and AT1 receptor inhibitors given prophy-
lactically (for the duration of obstruction) are beneficial in
alleviating nephropathy. Specifically, they reduce TGF-β
[121, 144] and TNF-α [106] expression, as well as macro-
phage infiltration and tubulointerstitial fibrosis [84, 105,
145]. Additionally, AT1 receptor inhibitors improve tubular
function by improving RBF and GFR and attenuating the
reduction in sodium transporter and aquaporin 2 (AQP2)
expression, thus reducing polyuria and natriuresis [92, 112].
ACE inhibitors reduce both AT1 and AT2 receptor stimu-
lation [146] and indirectly increase NO levels via bradykinin
generation [84]. This may explain why they confer additional
benefits, particularly anti-inflammatory, compared to AT1 re-
ceptor inhibitors [97]. Unfortunately, inhibition of angiotensin
during either the period of nephrogenesis (first 10 days after
UUO) or renal maturation (second 10 days after UUO) in
neonatal partial UUO exacerbates renal injury in both the
obstructed and contralateral kidney [147, 148]. Such studies
highlight the importance of these pathways in normal kidney
development and maturation.
However, it is important to remember that ACE inhibitors
and AT1 receptor inhibitors are frequently used in children
with chronic kidney disease, in whom they significantly
reduce proteinuria [149] despite not significantly alleviating
the natural decline in excretory function [150, 151]. They are
largely well tolerated, with no apparent effect on growth and
development and a low incidence of side effects such as
hyperkalaemia, hypotension and renal injury [149].
Hydroxymethylglutaryl-CoA reductase inhibitors
(statins)
Statins ameliorate nephropathy when administered prophylac-
tically in adult and neonatal rodent UUO models by reducing
Fig. 7 Transforming growth factor β1 (TGF-β1) signalling via the
SMAD-dependent pathway. Unilateral ureteric obstruction induces
increased TGF-β1 and TGF-β receptor II (TGFβRII) expression,
upregulating SMAD 2 and 3 and downregulating SMAD 7 (inhibitory
for SMAD 2 and 3). β1-integrin is upregulated by both SMAD signalling
and mechanical stretch and contributes to a positive feedback loop
regulating TGF-β1 expression via the c-SRC and STAT-3 pathways.
EMT Epithelial mesenchymal transformation
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renal cytokine production (TGF-β, TNF-α), macrophage
infiltration, oxidative stress, apoptosis and tubulointerstitial
fibrosis [85, 152, 153]. These pleiotropic effects are achieved
through decreased Ras/ERK/Akt signalling [154] and in-
creased NO bioavailability [155]. Importantly, statins remain
beneficial in neonatal rodent UUO where an improvement in
tubular dilatation and glomerular number and size are also
seen [67, 79, 85]. Functionally, in UUO models, statins im-
prove GFR and microalbuminuria [156] and increase urinary
concentrating ability via boosting AQP2 expression [157].
Statins are commonly used and usually well tolerated in
adults. Side effects of treatment include hepatic dysfunction,
diabetes mellitus, benign proteinuria, peripheral neuropathy,
myalgia and rhabdomyolysis [158]. A 10-year follow-up
study of children (≥8 years) treated with statins for familial
hypercholesterolaemia demonstrated that few discontinue
therapy due to side effects and that there were no serious
adverse reactions [159]. In that same study, growth, puberty
and educational parameters were also unaffected compared to
controls [159].
TGF-β modulation
Prophylactic TGF-β receptor inhibition is renoprotective in
adult rodent UUO models, reducing apoptosis, macrophage
infiltration, fibrosis, proximal tubular atrophy and atubular
glomeruli formation [117, 160]. Similarly, anti-TGF-β anti-
body treatment increases NOS expression while reducing ap-
optosis and fibrosis [110]. Conversely, prophylactic TGF-β
receptor inhibition in neonatal mouse UUO causes wide-
spread renal necrosis, exacerbating the injury in the obstructed
kidney and highlighting the differing responses to signalling
cascades during renal development [117].
Anti-TGF-β antibody treatment (GC1008) has been
trialled in human oncological disease and was generally well
tolerated. However, side effects included gingivitis, fatigue
and skin rashes, including keratoacanthoma and squamous
cell carcinoma development (melanoma patients only).
GC1008 treatment has not progressed beyond phase II clinical
trials as drug development was discontinued by the manufac-
turer [161].
COX-2 inhibition
In adult rodent bilateral ureteric obstruction COX-2 inhibition
alleviates AQP2 and sodium transporter downregulation and
improves post-obstructive polyuria, which would appear to be
beneficial [69]. Conversely, other studies have demonstrated
that both genetic COX-2 knockout and prophylactic COX-2
inhibition in adult rodent UUOmodels increase tubular injury,
apoptosis and fibrosis, thereby negating potential use in the
clinical setting [70, 162].
Chronic celecoxib (COX-2 inhibitor) use in children
demonstrates a similar frequency of adverse events to non-
selective non-steroidal anti-inflammatory drugs, which are
most frequently gastrointestinal side effects [163].
Other potential therapeutic options
Other potential therapeutic pathways include those that
are able to increase the vasoactive molecule NO, as this
has been shown to reduce tubulointerstitial fibrosis in
adult rodent UUO models [84]. Although both ACE
inhibitors and statins increase NO bioavailability, this
is an indirect effect at the expense of drug-related side
effects.
Dietary nitrate supplementation is a novel therapeutic
option which directly targets the NO pathway, increas-
ing NO generation via nitrite production. Nitrite also
has cytoprotective effects independent of NO by
influencing mitochondrial function [164], and when ad-
ministered during rodent ischaemia reperfusion studies
reduces renal injury [165].
Despite former concerns associating nitrates with
methaemoglobinaemia and carcinogenesis, the nitrate–
nitrite–NO pathway is increasingly implicated in a pro-
tective role in humans [166]. Further investigation of
dietary nitrate supplementation as a potential therapy
in obstructive nephropathy is warranted.
Urinary biomarkers
Identifying early urinary biomarkers in PUJO may be benefi-
cial for the diagnosis, management and prognosis of this
condition. Such biomarkers would enable timely detection
of children with ‘damaging’ hydronephrosis who require
surgery to protect renal function, while avoiding surgery in
those with ‘safe’ hydronephrosis.
Urinary biomarkers in animal studies
There is little data on urinary biomarkers from animal studies.
Proteomics using a rat UUO model demonstrated increased
urinary and renal levels of alpha-actinin-1 and moesin at
1 week which corresponded with histological evidence of
tubular injury. Following 3 weeks of UUO urine and renal
levels of vimentin, annexin A1 and clusterin were significant-
ly elevated, corresponding with substantial renal interstitial
fibrosis [167].
Urinary biomarkers in human studies
Many urinary cytokines, growth factors, chemokines, tubular
enzymes and tubular transport proteins have been investigated
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Table 5 Urinary proteins from studies in children with pelvi-ureteric junction obstruction
Urinary protein
(corrected for
creatinine)a
Primary
measured
group
Comparators Bladder urine protein level Sensitivity/
specificity/
accuracyb
Post-operative bladder urine
(compared to pre-operative)
Ref
ALP Pyeloplasty CMP Increased pre-operative Se 91.4%/ Sp
100%/ Ac 94%
Decreased 12 months
post-operative
[168]
Angiotensinogen Pyeloplasty Healthy control
CMP
Increased pre-operative Se 93.3%c/ Sp
60%c
[169]
B2-microglobulin PUJO* Healthy control Increased Decreased 42 months
post-operative
[170]
B2-microglobulin Pyeloplasty Healthy control No change [171]
Ca19-9 Pyeloplasty Healthy control
CMP
Increased pre-operative Se 76%d/Sp 85%d Decreased 3 months
post-operative
[172]
Ca19-9 Pyeloplasty Healthy control
Hydrocoele/renal
cyst
Increased pre-operative Se 100%e/ Sp
82.6%e
Decreased 3 months
post-operative
[173]
CyC Pyeloplasty Healthy control No change [171]
EGF PUJO* Healthy control Decreased (obstructed group
only)
No change [170]
EGF Pyeloplasty Healthy control Decreased pre-operative Increased [174]
EGF Pyeloplasty Healthy control Increased pre-operative Se 70.4%/Sp
69.2%
Decreased 3 months and 1 year
post-operative
[175]
EGF Pyeloplasty Healthy control No change [176]
ET-1 Pyeloplasty Healthy control
VUR
Renal stones
Increased pre-operative Se 74.3%/Sp 90%/
Ac 81.5%
Decreased 12 months
post-operative
[177]
γGT Pyeloplasty CMP Increased pre-operative Se 62.9%/Sp
100%/Ac 74%
Decreased 12 months
post-operative
[168]
HO-1 Pyeloplasty Healthy control
CMP
Increased pre-operative Se 72.2%c/Sp
78.1%c
Decreased 1 month
post-operative
[178]
IP-10 Pyeloplasty Healthy control No change [175]
KIM-1 Pyeloplasty Healthy control
CMP
Increased pre-operative Se 100%c/Sp
71.4%c
[179]
MCP-1 Pyeloplasty Healthy control Increased pre-operative Se 77.8%/Sp
69.2%
Decreased 3 months and 1 year
post-operative
[175]
MCP-1 PUJO* Healthy control Increased Decreased 42 months
post-operative
[170]
MCP-1 Pyeloplasty Healthy control Increased pre-operative [174]
MCP-1 Pyeloplasty Healthy control
CMP
Increased pre-operative Se 100%c/Sp 0%c Remains high 3 months
post-operative
[180]
MIP-1α Pyeloplasty Healthy control Decreased pre-operative Increased 1 year post-operative [175]
NAG Pyeloplasty CMP Increased pre-operative Se 97.1%/Sp
80%/Ac 92%
Decreased 12 months
post-operative
[168]
NGAL Pyeloplasty Healthy control No change [171]
NGAL Pyeloplasty Healthy control Increased pre-operative [181]
NGAL Pyeloplasty Healthy control
CMP
Increased pre-operative Se 100%c/Sp
28.6%c
Decreased 3 months
post-operative
[179]
OPN Pyeloplasty Healthy control No change [171]
OPN Pyeloplasty Healthy control
CMP
Increased pre-operative Se 98.5%c/Sp
10.5%c
Remains high 3 months
post-operative
[180]
RANTES Pyeloplasty Healthy control No change [175]
TGF-β Pyeloplasty Healthy control Increased pre-operative Se 100%/Sp
80%/Ac 90.8%
Decreased 1 year post-operative [176]
TGF-β Pyeloplasty CMP Increased pre-operative Se 82%/Sp 86% [182]
Generally, the primary group measured is children undergoing pyeloplasty; these children are then compared to healthy controls and/or conservatively
managed children with PUJO (CMP). The exception in the studies listed in the table is labelled PUJO*, which includes children with conservatively
managed PUJO split into ‘functional’ (t1/2 of renogram < 0 min) and ‘obstructed’ (t1/2 of renogram > 20 min). In these studies voided urine from
children undergoing pyeloplasty was only obtained 42 months post-operative
a ALP, Alkaline phosphatase; Ca19-9, carbohydrate antigen 19–9; CyC, cystatin-C; HO-1, heme oxygenase-1;γGT, gamma-glutamyl transferase; IP-10,
interferon-γ-inducible protein 10; KIM-1, kidney injury molecule-1; MIP-1α, macrophage inflammatory protein-1α; NAG, N-acetyl-beta-D-
glucosaminidase; NGAL, neutrophil gelatinase-associated lipocali; OPN, osteopontinn, RANTES, regulated on activation normal T-cell expressed
and secreted
bWhere applicable sensitivity (Se), specificity (Sp) and accuracy (Ac) of the test at best threshold value from receiver operating characteristic curve
analysis is presented
c To detect differential renal function (DRF) of <40% out of all hydronephrosis cases
d To detect pyeloplasty cases out of all hydronephrosis cases
e To detect pyeloplasty cases out of all cases
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in children undergoing pyeloplasty for PUJO. Studies with
conservatively managed PUJO as a comparator are most
useful to identify biomarkers able to aid selection of patients
for surgery. Potential urinary biomarker proteins measured in
bladder urine samples are presented in Table 5.
Finding a suitable biomarker test with high sensitivity,
specificity and predictive value is challenging [88], not least
because these markers are excreted in health as well as dis-
ease, show significant intra- and inter-patient variation and
may be affected by patient age, the presence of urinary tract
infection and other renal disorders [174, 183].
A recent systematic review of urinary and serum
biomarkers included 14 studies which reported data on 380
surgically managed PUJO patients, 174 conservatively man-
aged patients and 213 controls [184]. This review reported a
wide-range of sometimes conflicting results, and the authors
were unable to draw any firm conclusions, attributing this to
differences in study design with heterogeneous age groups,
various or absent control groups and often short durations of
follow-up [184].
More successfully, proteomics of neonatal urine has iden-
tified a panel of 51 peptides which distinguish obstruction
severity. When implemented in a prospective blinded study
it had an accuracy of 94% to predict future need for surgery in
newborns with PUJO [185]. However, beyond 1 year of age
the sensitivity and specificity of this proteome profile dimin-
ished significantly [186].
A single biomarker able to guide selection of patients for
pyeloplasty has not yet been identified, indicating a panel of
biomarkers may be necessary to achieve this.
Conclusions
Managing children with asymptomatic intrinsic PUJO is a
significant challenge for clinicians. Animal and human studies
have expanded our understanding of the molecular mecha-
nisms involved in the aetiology of obstruction and in particu-
lar the progression of the renal insult. Upregulation of the
RAAS and TGF-β expression are fundamental to renal injury,
which is attenuated in animal models by therapeutic inhibition
of these pathways. Much, however, remains to be learned in
order to identify molecular markers and targets useful in the
day-to-day diagnosis and management of this condition.
Future perspectives and unanswered questions
in PUJO
& What is the underlying aetiology of intrinsic congenital
PUJO? Does this explain the variable outcome of PUJO
and can this be targeted therapeutically?
& Does individual ability to relieve intra-renal pressure
determine disease progression?
& Are therapies tested in animals applicable in children to
limit renal injury?
& Can urinary biomarkers improve early identification and
thus outcome of children requiring pyeloplasty?
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